|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.10.25 - 04:36
|
atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire EN)
|
|
|
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 23,725,000 common shares, at a price of $5.48 per share. atai has granted the underwriters a 30-day option to purchase up to an additional 3,558,750 common shares at the public offering price, less the underwriting discount. All common shares to be sold in the offering will be sold by atai....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.09.25 - 14:03
|
atai Life Sciences Awarded Grant from the National Institutes of Health (GlobeNewswire EN)
|
|
|
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai's novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai's novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
